BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1784631)

  • 1. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules.
    Himes RH
    Pharmacol Ther; 1991; 51(2):257-67. PubMed ID: 1784631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
    Owellen RJ; Hartke CA; Dickerson RM; Hains FO
    Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB; Tuszynski JA; Klobukowski M
    J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline.
    Prakash V; Timasheff SN
    Biochemistry; 1991 Jan; 30(3):873-80. PubMed ID: 1988072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
    Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
    Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
    Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
    Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
    Zhang Y; Yang SH; Guo XL
    Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aging of tubulin at neutral pH: the destabilizing effect of vinca alkaloids.
    Prakash V; Timasheff SN
    Arch Biochem Biophys; 1992 May; 295(1):137-45. PubMed ID: 1575510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubules as drug receptors: pharmacological properties of microtubule protein.
    Wilson L
    Ann N Y Acad Sci; 1975 Jun; 253():213-31. PubMed ID: 1096718
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel aspects of natural and modified vinca alkaloids.
    Duflos A; Kruczynski A; Barret JM
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
    Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
    Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of drugs on microtubules.
    Wilson L
    Life Sci; 1975 Aug; 17(3):303-9. PubMed ID: 1099380
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of hybrid molecules targeting the vinca domain of tubulin.
    Gherbovet O; Sánchez-Murcia PA; García Alvarez MC; Bignon J; Thoret S; Gago F; Roussi F
    Org Biomol Chem; 2015 Mar; 13(10):3144-54. PubMed ID: 25634805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.